



## Correction to: Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

Shusuke Yagi<sup>1</sup> · Takeru Wakatsuki<sup>1</sup> · Noriko Yamamoto<sup>2</sup> · Keisho Chin<sup>1</sup> · Daisuke Takahari<sup>1</sup> · Mariko Ogura<sup>1</sup> · Takashi Ichimura<sup>1</sup> · Izuma Nakayama<sup>1</sup> · Hiroki Osumi<sup>1</sup> · Eiji Shinozaki<sup>1</sup> · Mitsukuni Suenaga<sup>1</sup> · Junko Fujisaki<sup>1</sup> · Yuichi Ishikawa<sup>1</sup> · Kensei Yamaguchi<sup>1</sup> · Ken Namikawa<sup>1</sup> · Yusuke Horiuchi<sup>1</sup>

Published online: 22 November 2018

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2018

### Correction to: Gastric Cancer

<https://doi.org/10.1007/s10120-018-0887-x>

In the original publication of this article, Table 4 was published incorrectly. The correct Table 4 is given below.

The original article has been corrected. Publisher sincerely apologizes for the error.

**Table 4** Comparison survivals between surgical specimens and biopsy specimens

	Biopsy specimens	Surgical specimens
mPFS		
Homo-HER2	10.8 (95% CI 6.9–19.4)	20.0 (95% CI 17.8–22.2)
Hetero-HER2	6.1 (95% CI 5.3–8.2)	6.0 (95% CI 2.3–9.7)
mOS		
Homo-HER2	29.3 (95% CI 20.5–NR)	NR
Hetero-HER2	14.4 (95% CI 11.4–17.8)	14.0 (95% CI 11.9–16.1)

*mPFS* median progression-free survival, *mOS* median overall survival, *NR* not reached, *Homo-HER2* homogeneously HER2 positive, *Hetero-HER2* heterogeneously HER2 positive

The original article can be found online at <https://doi.org/10.1007/s10120-018-0887-x>.

✉ Takeru Wakatsuki  
takeru.wakatsuki@jfc.or.jp

Ken Namikawa  
ken.namikawa@jfc.or.jp

Yusuke Horiuchi  
yusuke.horiuchi@jfc.or.jp

<sup>1</sup> Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

<sup>2</sup> Department of Pathology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan